OBJECTIVE: To estimate the incidence of genetic counseling referral for ovarian cancer patients who are at substantial risk for a BRCA1 or BRCA2 mutation. METHODS: An analysis was performed of new ovarian cancer patients who were seen at a comprehensive cancer center from January 1, 1999, through December 31, 2007. Patients at substantial (more than 20-25%) risk for a BRCA1 or BRCA2 mutation were identified and records reviewed for referral to genetic counseling. Time to referral was estimated using the Kaplan-Meier method. RESULTS: A total of 3,765 epithelial ovarian cancer patients were seen during the 9-year period. On average, 23.8% of patients met substantial-risk criteria for BRCA mutations. In 1999, only 12% of patients at substantial-risk were referred. Referral improved over time with 48% referred in 2007 (P<.001). Newly diagnosed patients were more often referred for genetic counseling than new patients with recurrent disease or those seen as second opinions. African-American women meeting substantial-risk criteria were less likely to be referred than were white or Hispanic women (P=.009). CONCLUSION: Although dictated family history was accurate, interpretation of risk for BRCA1 or BRCA2 mutations and subsequent referral to genetic counseling was poor. Although there was significant improvement over time, 50% of substantial-risk patients still were missed. Systematic efforts to identify those ovarian cancer patients at substantial risk for a BRCA1 or BRCA2 are necessary.
OBJECTIVE: To estimate the incidence of genetic counseling referral for ovarian cancerpatients who are at substantial risk for a BRCA1 or BRCA2 mutation. METHODS: An analysis was performed of new ovarian cancerpatients who were seen at a comprehensive cancer center from January 1, 1999, through December 31, 2007. Patients at substantial (more than 20-25%) risk for a BRCA1 or BRCA2 mutation were identified and records reviewed for referral to genetic counseling. Time to referral was estimated using the Kaplan-Meier method. RESULTS: A total of 3,765 epithelial ovarian cancerpatients were seen during the 9-year period. On average, 23.8% of patients met substantial-risk criteria for BRCA mutations. In 1999, only 12% of patients at substantial-risk were referred. Referral improved over time with 48% referred in 2007 (P<.001). Newly diagnosed patients were more often referred for genetic counseling than new patients with recurrent disease or those seen as second opinions. African-American women meeting substantial-risk criteria were less likely to be referred than were white or Hispanic women (P=.009). CONCLUSION: Although dictated family history was accurate, interpretation of risk for BRCA1 or BRCA2 mutations and subsequent referral to genetic counseling was poor. Although there was significant improvement over time, 50% of substantial-risk patients still were missed. Systematic efforts to identify those ovarian cancerpatients at substantial risk for a BRCA1 or BRCA2 are necessary.
Authors: J Peto; N Collins; R Barfoot; S Seal; W Warren; N Rahman; D F Easton; C Evans; J Deacon; M R Stratton Journal: J Natl Cancer Inst Date: 1999-06-02 Impact factor: 13.506
Authors: F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: Y Ben David; A Chetrit; G Hirsh-Yechezkel; E Friedman; B D Beck; U Beller; G Ben-Baruch; A Fishman; H Levavi; F Lubin; J Menczer; B Piura; J P Struewing; B Modan Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog Journal: Gynecol Oncol Date: 2007-11 Impact factor: 5.482
Authors: T S Frank; S A Manley; O I Olopade; S Cummings; J E Garber; B Bernhardt; K Antman; D Russo; M E Wood; L Mullineau; C Isaacs; B Peshkin; S Buys; V Venne; P T Rowley; S Loader; K Offit; M Robson; H Hampel; D Brener; E P Winer; S Clark; B Weber; L C Strong; A Thomas Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu Journal: Gynecol Oncol Date: 2017-06-10 Impact factor: 5.482
Authors: Kristin B Niendorf; Melissa A Geller; Rachel Isaksson Vogel; Timothy R Church; Anna Leininger; Angela Bakke; Robert D Madoff Journal: Fam Cancer Date: 2016-10 Impact factor: 2.375
Authors: Margot M Koeneman; Arnold-Jan Kruse; Simone J S Sep; Cynthia S Gubbels; Brigitte F M Slangen; Toon van Gorp; Alberto Lopes; Encarna Gomez-Garcia; Roy F P M Kruitwagen Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375
Authors: Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus Journal: Cancer Prev Res (Phila) Date: 2014-04-25
Authors: Sue V Petzel; Rachel Isaksson Vogel; Tracy Bensend; Anna Leininger; Peter A Argenta; Melissa A Geller Journal: J Genet Couns Date: 2013-05-16 Impact factor: 2.537